Delta-type opioid receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats Delta-type opioid receptor as ChEMBL target CHEMBL3222, mapped to UniProt P32300. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why Delta-type opioid receptor matters
Delta-type opioid receptor is reviewed as Delta-type opioid receptor (UniProt P32300); the current evidence base includes 11 approved drugs, 2054 compounds, and 565 assays, with lead potency reaching pChEMBL 11.0.
Delta-type opioid receptor Sequence length is 372 aa.
Review this target as Delta-type opioid receptor, mapped to UniProt P32300. Sequence length is 372 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 11 approved drugs, 2054 compounds, and 565 assays for this target. The dominant activity type is IC50. CHEMBL196774 is the current potency anchor at pChEMBL 11.0.
Use CHEMBL196774 as the tractability anchor when discussing potency (pChEMBL 11.0).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why Delta-type opioid receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P32300, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL196774
|
11.0 | Kd | — |
|
|
No preferred name
CHEMBL373192
|
11.0 | Kd | — |
|
|
No preferred name
CHEMBL607401
|
10.8 | IC50 | — |
|
|
No preferred name
CHEMBL339320
|
10.8 | IC50 | — |
|
|
No preferred name
CHEMBL129252
|
10.8 | IC50 | — |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
NALFURAFINE
CHEMBL267495
|
2009 |
|
|
NALFURAFINE HYDROCHLORIDE
CHEMBL490665
|
2009 |
|
|
NALTREXONE
CHEMBL19019
|
1984 |
|
|
MORPHINE
CHEMBL70
|
1984 |
|
|
NALOXONE
CHEMBL80
|
1971 |
|
|
FENTANYL
CHEMBL596
|
1968 |
|
|
FENTANYL CITRATE
CHEMBL688
|
1968 |
|
|
OXYMORPHONE
CHEMBL963
|
1959 |